About this Research Topic
Cancer is one of the leading causes of death worldwide and a major obstacle to increasing human life expectancy. Engineered cell-originated biomimetic materials have emerged as attractive cancer therapeutic agents. The main engineering modification strategies include genetic engineering, encapsulation, and surface modification. Engineering modifications can further enhance the biological properties of cell primitives such as targeting and immunogenicity, thus increasing drug accumulation in tumors or enhancing the effect of tumor immunotherapy. Drawbacks of synthetic materials can be overcome through a combination of engineered cell primitives and organic or inorganic nanomaterials. Many research teams have generated innovative, biocompatible, and multifunctional biomaterials applied in immunotherapy, drug delivery, and photothermal therapy for tumors.
The aim of this research topic is to provide comprehensive coverage of the relevant topics concerning the application of engineered cell-originated biomimetic materials for oncology therapeutics, including expert reviews and original research articles. Special emphasis will be given to studies that create new engineering strategies to improve the immunotherapeutic efficacy of cancer vaccines, sensitize conventional oncology therapies, improve drug delivery efficiency, or provide insight into the therapeutic mechanisms of materials. We call for reviews that systematically and comprehensively evaluate the latest advances in engineered cell primitive-based biomimetic materials for cancer therapy. We are also very interested in formulations that have promising clinical applications in cancer therapy.
The scope of this Research Topic covers but is not limited to:
• biomaterials (e.g., hydrogel, nanoparticle, electrospun fibers, etc.) using functionalized whole cells for tumor therapy
• therapeutic nanoparticles encapsulated by whole cells such as cancer cells, stem cells, bacteria, etc.
• nanoparticles camouflaged by cellular components (e.g., vesicles, exosomes, cell membranes)
• bacteria-based functional materials for cancer treatment, including both live bacteria and bacteria extracts
• phage-based functional materials for cancer treatment
• live algae and algae extracts based functional materials for cancer therapy
• cell membrane surface modified materials
• reviews that systematically evaluate progress in this field
The aim of this research topic is to provide comprehensive coverage of the relevant topics concerning the application of engineered cell-originated biomimetic materials for oncology therapeutics, including expert reviews and original research articles. Special emphasis will be given to studies that create new engineering strategies to improve the immunotherapeutic efficacy of cancer vaccines, sensitize conventional oncology therapies, improve drug delivery efficiency, or provide insight into the therapeutic mechanisms of materials. We call for reviews that systematically and comprehensively evaluate the latest advances in engineered cell primitive-based biomimetic materials for cancer therapy. We are also very interested in formulations that have promising clinical applications in cancer therapy.
The scope of this Research Topic covers but is not limited to:
• biomaterials (e.g., hydrogel, nanoparticle, electrospun fibers, etc.) using functionalized whole cells for tumor therapy
• therapeutic nanoparticles encapsulated by whole cells such as cancer cells, stem cells, bacteria, etc.
• nanoparticles camouflaged by cellular components (e.g., vesicles, exosomes, cell membranes)
• bacteria-based functional materials for cancer treatment, including both live bacteria and bacteria extracts
• phage-based functional materials for cancer treatment
• live algae and algae extracts based functional materials for cancer therapy
• cell membrane surface modified materials
• reviews that systematically evaluate progress in this field
Keywords: Cancer immunotherapy, Cancer vaccine, Nanovaccine, Cell primitives, Cell membrane camouflage, Biomimetic material, Engineered Nanoparticle, Whole-cell vaccines, Bacteria-based cancer vaccine
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
